Regulatory flexibility can make continuous improvement possible.
Stefanie Pluschkell
Advertisement
Stefanie Pluschkell is an associate research fellow in global CMC, biologics and devices, at Pfizer Inc.
Articles by Stefanie Pluschkell
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3Published: January 1st 2010 | Updated:
Quality by Design for Biotechnology Products—Part 2Published: December 1st 2009 | Updated:
Quality by Design for Biotechnology Products—Part 1Published: November 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
$1.8M RedHill Deal Highlights Growing Worldwide Focus on H. pylori Treatment Access
5
